Figure 4.

Anthrax LT treatment reduces c-Jun by disrupting MAPK signaling pathways. A and B, Hepa1c1c7 cells were left untreated (M) or treated with LT for 1, 2, and 4 h. Cell lysates were subjected to Western blot analysis for assessing protein levels of various MKKs (A) and total and phosphorylated Erk1/2, p38, and JNK1/2 (B). C, Hepa1c1c7 cells were left untreated or treated with the MAPK inhibitors U0126, SB203580, and SP600125 for 1, 2, 3, and 4 h. The levels of c-Jun protein in treated cells were determined by Western blotting. β-Actin was used as a loading control. Data shown are representative of three independent experiments. The intensities of protein bands were quantified using the Image Studio software of the Odyssey system and normalized by the amounts of β-actin; relative amounts are shown below each lane.